Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Emerge Weight Loss vs FlyteHealth

Emerge Weight Loss
Graded #447

Lower grade

vs+3.5
FlyteHealth
Graded #364

Higher grade

The verdict

FlyteHealth takes it — 58.6/100 to 55.1/100.

FlyteHealth grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. FlyteHealth is an obesity-medicine telehealth platform distributed mainly through employers, payers, and health plans, with care led by board-certified obesity-medicine physicians plus nurse practitioners,…

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueFlyteHealth +9
36
45
Dose & formulationEmerge Weight Loss +2
42
40
Clinical oversightEmerge Weight Loss +1
84
83
Labs & monitoringFlyteHealth +19
54
73
FulfillmentEmerge Weight Loss +8
70
62
Contract termsEven
55
55
Emerge Weight Loss · left barFlyteHealth · right bar

The numbers

MetricEmerge Weight LossFlyteHealth
WeighScore55.1/10058.6/100
GradeCC
Scorecard rank#447#364
SemaglutideNot disclosedNot disclosed
Tirzepatide$287/mo (2.5 mg dose, compounded)Not disclosed
CoverageCoverage not publishedCoverage not published
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyInjection only
Emerge Weight Loss

Graded #447 · C

Strengths

  • Tirzepatide-focused (largest effect-size compounded GLP-1)
  • Wide dose range available
  • Physician-supervised telemedicine model

Where it loses points

  • Semaglutide is available only on request — the site and default plans are tirzepatide-only
  • Less brand recognition than Henry Meds, Mochi, or SkinnyRx
FlyteHealth

Graded #364 · C

Strengths

  • Care led by board-certified obesity-medicine physicians
  • Multidisciplinary team with NPs, dietitians, and care coordinators
  • Published outcomes of about 13 to 16 percent weight loss over 12 months
  • High GLP-1 medication adherence (around 86 percent in reported data)
  • Comprehensive cardiometabolic care beyond GLP-1 alone

Where it loses points

  • Distributed primarily via employers, payers, and health plans, not direct cash-pay
  • Access is largely gated behind employer or plan sponsorship
  • GLP-1 is prescribed only when appropriate, not guaranteed
  • Self-pay pricing is not publicly listed (contact required)
  • Less suited to consumers wanting fast direct-to-door GLP-1

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard